ArticleJournal of gastroenterology2023

Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Reika Yamauchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.